NCT00034853已完成3 期
A 12 Week Double-blind Randomized Trial, With a 12 Week Open-label Extension, to Investigate the Efficacy and Safety of Meloxicam Oral Suspension Administered Once Daily and Naproxen Oral Suspension Administered Twice Daily in Children With Juvenile Rheumatoid Arthritis
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 180
- 试验地点
- 44
- 主要终点
- Responder rate by core set of outcome criteria (Juvenile Rheumatoid Arthritis Pediatric 30): global assessment disease activity; functional disability, number joints arthritis, limited motion; erythrocyte sedimentation rate;
研究概览
简要总结
To obtain safety, efficacy, pharmacokinetic and dosing information for meloxicam oral suspension in children with Juvenile Rheumatoid Arthritis (JRA)
研究设计
- 研究类型
- Interventional
- 干预模型
- Parallel
- 主要目的
- Treatment
入排标准
- 年龄范围
- 2 Years 至 17 Years（Child）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •diagnosis of juvenile idiopathic arthritis (JIA) by International League of Associations for Rheumatology (ILAR) criteria; pauciarthritic, extended pauciarthritic, or polyarthritic current course of disease;
- •active arthritis of at least 2 joints
- •at least 2 other abnormal variables of the 5 remaining core set parameters
- •require nonsteroidal anti-inflammatory drugs (NSAIDs)
- •children aged 2-17 years
排除标准
- •systemic course of juvenile idiopathic arthritis
- •all rheumatic conditions not included in inclusion criteria; any clinical finding or abnormal clinically relevant lab (not due to JIA) that could interfere with conduct of clinical trial
- •weight of 9 kg or less
- •pregnancy or breast feeding
- •females of childbearing potential who are sexually active and not using adequate contraception for at least 3 mos prior to and for duration of study
- •history of bleeding disorder, gastrointestinal bleeding, or cerebrovascular bleeding
- •peptic ulcer past 6 months
- •more than 1 disease modifying anti-rheumatic drug (DMARD) or change in DMARD during 3 months prior
- •change corticosteroids during 1 month prior
- •systemic corticosteroids greater than 10 mg/d, hydroxychloroquine greater than 10/mg/d, cyclosporine greater than 5 mg/kg/d., methotrexate greater than 15 mg/m2/wk, cytotoxic agents, gold, D-penicilamine, sulfasalazine, glucosamine, and investigational products
- •etanercept during 1 month prior; infliximab during 2 months prior; intra-articular corticosteroids during 1 month prior
- •patients requiring concomitant other NSAID including topical (excluding ophthalmic)
- •requirement for use of other NSAIDs, anticoagulants, phenothiazine, lithium, or ACTH
- •insufficient effect or intolerability to naproxen or meloxicam
- •known or suspected hypersensitivity to trial meds or their excipients
- •requirement of chronic H2 antagonist
- •history of asthma, nasal polyps, angioneurotic edema, or urticaria with aspirin or NSAIDs
- •planned surgical procedures during study
- •investigational drug exposure during this trial or within 30 days (or 6 half lives, whichever greater) prior
- •previous participation in this trial
- •patients with known drug or alcohol abuse
- •patient, parent or legal representative unable to understand and to comply with protocol
结局指标
主要结局
Responder rate by core set of outcome criteria (Juvenile Rheumatoid Arthritis Pediatric 30): global assessment disease activity; functional disability, number joints arthritis, limited motion; erythrocyte sedimentation rate;
时间窗: week 12
次要结局
- Individual core set outcome criteria; final global assessment of efficacy; tolerability; AE incidence and intensity; withdrawals; acetaminophen consumption; safety labs: physical examination; hospitalization for gastrointestinal (GI) SAE, GI AE(weeks 4, 8, 12, 18, and 24)
研究者
研究点 (44)
Loading locations...
相似试验
已完成
4 期
Efficacy and Safety of Meloxicam Suspension Versus Diclofenac Suspension or Nimesulide Suspension in Patients With a Diagnosis of Acute, Non-bacterial Pharyngitis, Pharyngotonsillitis or LaryngitisPharyngitisNCT02229747Boehringer Ingelheim128
已完成
3 期
A One Year Double-blind Trial to Investigate the Efficacy and Safety of Meloxicam Oral Suspension in Juvenile Rheumatoid Arthritis (JRA/JIA)Arthritis, Juvenile RheumatoidNCT00279747Boehringer Ingelheim226
已完成
4 期
Effect of Meloxicam Tablets on Bleeding Time in Healthy SubjectsHealthyNCT02183155Boehringer Ingelheim82
尚未招募
2 期
Efficacy, Safety and Tolerability Study of Meloxicam Injection in Subjects After Abdominal SurgeryPain, Post-operativeNCT05950152Beijing Tide Pharmaceutical Co., Ltd108
已完成
3 期
A Study to Compare Meloxicam IM Once Daily and Meloxicam Administered Orally Once Daily in Patients With OsteoarthritisOsteoarthritisNCT00239395Boehringer Ingelheim168